Modality
Vaccine
MOA
CFTRmod
Target
GLP-1R
Pathway
NF-κB
AML
Development Pipeline
Preclinical
~Apr 2015
→ ~Jul 2016
Phase 1
~Oct 2016
→ ~Jan 2018
Phase 2
Apr 2018
→ Feb 2029
Phase 2Current
NCT08151745
1,631 pts·AML
2018-04→2025-04·Recruiting
NCT08546851
2,861 pts·AML
2023-01→2029-02·Terminated
4,492 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-04-2211mo agoPh3 Readout· AML
2029-02-032.8y awayPh3 Readout· AML
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
P2/3
Recruit…
P2/3
Termina…
Catalysts
Ph3 Readout
2025-04-22 · 11mo ago
AML
Ph3 Readout
2029-02-03 · 2.8y away
AML
RecruitingTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08151745 | Phase 2/3 | AML | Recruiting | 1631 | EDSS |
| NCT08546851 | Phase 2/3 | AML | Terminated | 2861 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2191 | Pfizer | NDA/BLA | GLP-1R | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| Tirzepatide | Eli Lilly | Approved | GLP-1R | |
| LLY-4358 | Eli Lilly | Phase 3 | B7-H3 | |
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| Gelinaritide | AbbVie | Preclinical | FcRn | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| Mavuglumide | Bayer | Approved | GLP-1R | |
| Bemarelsin | Daiichi Sankyo | Preclinical | GLP-1R |